Updated July 18, 2026
The Endocrine Society's ENDO 2026 conference dropped data that shifted how researchers think about GLP-1 medications and male reproduction. For the first time, large-scale observational data addressed the question men have been asking their providers for two years: does this drug affect my ability to have kids?
WHAT THE STUDIES MEASURED
Three presentations at ENDO 2026 examined GLP-1 receptor agonists and male reproductive markers. Unlike earlier case reports — which tracked individual patients and generated alarming but statistically meaningless headlines — these were properly powered observational studies with control groups.
The primary endpoints included semen parameters (concentration, motility, morphology), hormonal panels (testosterone, FSH, LH, estradiol), and self-reported fertility outcomes in men aged 25 to 45 who had been on semaglutide or tirzepatide for at least six months.
⚡ Why this matters for men specifically
GLP-1 medications were primarily studied in mixed-gender populations during clinical trials. Male-specific reproductive outcomes were not primary endpoints in any Phase III trial. The ENDO 2026 data is the first to address male fertility with statistical rigor.
THE TESTOSTERONE VARIABLE
The most consistent finding across the ENDO 2026 presentations was a testosterone increase associated with GLP-1-mediated weight loss. This is not surprising — obesity suppresses testosterone through increased aromatase activity (the enzyme that converts testosterone to estrogen in fat tissue). Lose fat, reduce aromatase, and testosterone tends to recover.
What was new: the magnitude. Men who lost 15% or more of body weight on GLP-1 medications showed average testosterone increases of 100 to 200 ng/dL over 12 months. For a man starting at 350 ng/dL (low-normal), that bump to 450–550 could be clinically meaningful — potentially enough to improve semen parameters that were suppressed by the original low-T state.
The caution: this is an indirect effect. The GLP-1 did not directly increase testosterone. It facilitated weight loss, which reduced aromatase, which allowed testosterone to normalize. Men who did not lose significant weight on GLP-1s did not see this hormonal recovery.
⚠️ Correlation, not prescription
The ENDO 2026 data shows association between GLP-1-mediated weight loss and improved male hormonal profiles. It does not establish GLP-1 medications as a fertility treatment. If you are actively trying to conceive, discuss your specific situation with a reproductive endocrinologist.
SEMEN PARAMETERS
The sperm quality data was more nuanced. One study found no statistically significant change in semen concentration or motility after 6 months of semaglutide use. Another found a modest improvement in motility (but not concentration) that the authors attributed to the testosterone recovery described above rather than a direct GLP-1 effect on spermatogenesis.
Neither study found evidence that GLP-1 medications harm sperm production or quality. This is the finding that matters most for men concerned about fertility: at the population level, the drugs do not appear to impair male reproductive function.
The one area of ongoing uncertainty is the effect of rapid weight loss itself — independent of GLP-1 medication — on male fertility. Severe caloric restriction is known to temporarily suppress reproductive hormones in both men and women. Men losing weight rapidly on GLP-1s may experience a transient dip in reproductive markers during the most aggressive phase of weight loss, followed by recovery as weight stabilizes.
Bodybuilding.com GLP-1 — From $199/mo
GLP-1 and longevity prescriptions from the fitness industry's largest platform.
GLP-1 and longevity prescriptions from a platform built for men who train.
Paid link · Compounded medications are not FDA-approved and are prepared by state-licensed pharmacies.
WHAT THIS MEANS FOR YOU
If you are a man considering or currently taking a GLP-1 medication and fertility is on your radar — actively trying, planning within the next year, or generally wanting to preserve the option — the ENDO 2026 data offers cautious reassurance.
The data does not suggest GLP-1s impair male fertility. Unlike some medications used for weight management (phentermine, for example, which carries reproductive warnings), GLP-1 receptor agonists have not shown negative effects on semen parameters in the available data.
Weight loss itself may improve your fertility picture. If obesity is contributing to low testosterone and suboptimal semen quality, the testosterone recovery associated with GLP-1-mediated weight loss could actually improve reproductive outcomes.
But the research is still young. These are observational studies with 6-to-12-month follow-up. We do not have multi-year data on men who use GLP-1 medications through their reproductive years. If you are actively trying to conceive and have any concerns, a baseline semen analysis and hormonal panel before starting — and follow-up testing at 6 months — gives you personal data rather than population averages.
Injectable and lozenge semaglutide with 120-day/5% guarantee. Sublingu...
Compounded tablets — semaglutide $147/mo, tirzepatide $249/mo. Metabol...
RELATED INTEL
GLP-1s and Sperm Quality →The 40% Lean Mass Warning →Protein Timing for Men on GLP-1s →Sources: ENDO 2026 conference abstracts; published observational data on GLP-1 receptor agonists and male reproductive endocrinology. Specific study citations available in the referenced presentations. This article does not constitute medical or fertility advice.